ARTICLE | Company News
JW grants Leo rights to atopic dermatitis candidate JW1601
August 31, 2018 6:30 PM UTC
JW Pharmaceutical Corp. (KSE:001060) granted Leo Pharma A/S (Ballerup, Denmark) exclusive rights to develop and commercialize JW1601 worldwide, excluding Korea. This year, JW expects to submit an IND in Korea for a Phase I trial of the product, which it intends to develop to treat atopic dermatitis.
JW will receive $17 million up front and is eligible for $385 million in development and sales milestones, plus royalties up to double digits...
BCIQ Target Profiles